To obtain a gastrointestinal drug which contains the combination of Coptidis rhizoma and/or Pbellodendri cortex puverata and Aurantii nobilis pericarpium pulveratum, possesses anti-Helicobacter pylori activity and is useful in the prevention, the treatment or the recidivation prevention for gastritis, gastric ulcer, duodental ulcer or the like.
This gastrointestinal drug is obtained by including the combination of (A) Coptidis rhizoma and/or Phellodendri cortex pulverata or extracts and (B) Aurantii nobilis pericarpium pulveratum or extract. On this gastrointestinal drug, it is favorable to use 2-200 pts.wt. of the raw crude drug of the component B based on 1 pt.wt. of the raw crude drug of the component A. Further, it is favorable that this gastrointestinal drug includes at least one kind of histamine H2 receptor antagonist (e.g. cimetidine or the like), proton pump inhibitor (e.g. lansoprazole or the like), gastric mucosa protection type gastritis-peptic ulcer therapeutic drug (e.g. aldioxa or the like), antacid and stegnotic. On the amounts of the components A and B used, Coptidis rhizoma and Phellodendri cortex or Aurantii nobilis pericarpium are preferably used at daily doses of 0.03-6 g and 0.03-10 g, respectively, per an adult based on the raw crude drugs.
NAKAO MASAFUMI
OKUNO KENJI
